|Bid||0.0000 x 4000|
|Ask||0.0000 x 4000|
|Day's Range||1.9200 - 1.9900|
|52 Week Range||1.9200 - 5.2400|
|Beta (5Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 18, 2012|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for SPPILearn more
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates in
NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the November 1, 2021deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) from December 27, 2018 through August 5, 2021 (the "Class Period").